Stable activatable particles as radiotherapeutic agents for the treatment of disease
Patent Number: US9327038
Executive Summary:
General Description:
Administration of therapeutic radionuclides targeted to specific tumor cells have been proven to be a successful therapy. Targeted radionuclide therapy is based on the emission of ionizing radiation by the radionuclides, which is absorbed by the cancer cells and results in tumor regression. This invention uses stable, activatable radioparticles for targeted therapy, which can be activated locally after administration of the precursor.
Strengths:
Weaknesses:
Patent Status:
Inventor Bio: Michael Jay
https://pharmacy.unc.edu/news/directory/mjay/
Executive Summary:
- Invention Type: Therapeutic
- Patent Status: Active
- Patent Link: https://patents.google.com/patent/US9327038/
- Research Institute: University of North Carolina
- Disease Focus: Cancers treatable by radiotherapy
- Basis of Invention: Activatable radioactive precursors
- How it works: A stable particle that contains an activatable radionuclide precursor linked to a silica carrier with a tumor-targeting agent and a hydrophobic/lipophilic moiety. After administration of a therapeutically effective dose to the patient, the particle can locally be activated through neutron activation
- Lead Challenge Inventor: Michael Jay
- Inventors: Anthony J. Di Pasqua, Xiuling Lu, Michael Jay
- Development Stage: Pre-clinical
- Novelty:
- Use of activatable radioparticles for targeted radionuclide therapy
- Clinical Applications:
- Targeted radionuclide therapy
- Targeted radionuclide therapy
General Description:
Administration of therapeutic radionuclides targeted to specific tumor cells have been proven to be a successful therapy. Targeted radionuclide therapy is based on the emission of ionizing radiation by the radionuclides, which is absorbed by the cancer cells and results in tumor regression. This invention uses stable, activatable radioparticles for targeted therapy, which can be activated locally after administration of the precursor.
Strengths:
- Can be customized
- Reduced toxicity compared to other radiotherapies
- Safe handling by manufacturers
- Limits time constraints imposed by decay/half-life
Weaknesses:
- Molecular targets need to be optimized
Patent Status:
- Filing date: 2012-10-25
Inventor Bio: Michael Jay
https://pharmacy.unc.edu/news/directory/mjay/
